Anavex (AVXL) Life Sciences announced the successful completion of enrollment in its Phase 2 clinical study of ANAVEX3-71 for the treatment of schizophrenia. The study has enrolled a total of 71 participants, with 16 participants in Part A and 55 participants in Part B. Part A of the study, which investigated multiple ascending doses, has been completed with encouraging preliminary safety and electroencephalography biomarker results previously reported. Part B, which includes more participants and a longer treatment duration, will provide more comprehensive clinical and biomarker data on the efficacy and safety of ANAVEX3-71 in individuals with schizophrenia.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVXL:
- Anavex appoints Audrey Gabelle to Scientific Advisory Board
- Largest borrow rate increases among liquid names
- Promising Potential of Anavex Life Sciences’ Blarcamesine in Alzheimer’s Treatment Reinforces Buy Rating
- Anavex announces results from Phase IIb/III open-label extension trial
- Buy Rating for Anavex: Capitalizing on European Market Opportunities Amid Eli Lilly’s Setback